報價延遲最少15分鐘:2026/03/28 17:37 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.28 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.76/0.40
|
|
企業價值
236.91M
|
| 資產負債 |
|
每股賬面淨值
10.71
|
| 現金流量 |
|
現金流量率
0.05
|
| 損益表 |
|
收益
112.82M
|
|
每股收益
11.32
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries. |
